Supporting Information

The following Supporting information is available for this article:

Table S1. Genomic position of H19 and IGF2 CpG sites investigated by Illumina microarray and by MS-MLPA

Table S2. Microarray sites from imprinted genes other than IGF2/H19

Table S3. Aberrantly methylated microarray sites from imprinted genes other than IGF2/H19

Table S4. KCNQ1 microarray and MS-MLPA sites

Table S5. Most significant hits from microarray CpG site analysis of imprinted genes

Table S6. Clinical characteristics of SRShypo patients with a high percentage (≥4%) of aberrantly methylated imprinted loci in addition to IGF2/H19 (subgroup Strong multilocus defect) and without (0%; subgroup Restricted defect)

Additional Supporting information may be found in the online version of this article.

CGE_1844_sm_TableS1-S6.pdf431KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.